Congress Is Suddenly Waking Up to the AI Doomsday Threat31m ago Extreme Networks’ Agent ONE Coworker moves AI networking from dashboards to answers40m ago Introducing ChatGPT for Financial Services44m ago Tesla unveils driverless Cybercab in Japan for 1st time1h ago The AI safety vibe shift2h ago Sam Altman met with top power utilities about securing the electrical grid. He offered one possible solution: OpenAI's cyber services.2h ago OpenAI Is Open to Slowing Cutting-Edge AI, CEO Sam Altman Tells Staff2h ago Tencent-Backed Chipmaker Enflame Jumps 188% in Shanghai Debut2h ago Salesforce introduces Enterprise AI Harness, AI Control Plane2h ago The Race for the Next Big Weight-Loss Drug Is On—and China Wants In3h ago How Social Media Platforms Are Identifying AI Content3h ago DeepSeek launches V4.1-Flash and retires V4-Pro, its flagship model3h ago OpenAI Wants to Know if an AI Industry Slowdown Would Even Be Legal3h ago Oracle Cloud Sales More Than Double, Topping Estimates on AI4h ago

Congress Is Suddenly Waking Up to the AI Doomsday Threat31m ago Extreme Networks’ Agent ONE Coworker moves AI networking from dashboards to answers40m ago Introducing ChatGPT for Financial Services44m ago Tesla unveils driverless Cybercab in Japan for 1st time1h ago The AI safety vibe shift2h ago Sam Altman met with top power utilities about securing the electrical grid. He offered one possible solution: OpenAI's cyber services.2h ago OpenAI Is Open to Slowing Cutting-Edge AI, CEO Sam Altman Tells Staff2h ago Tencent-Backed Chipmaker Enflame Jumps 188% in Shanghai Debut2h ago Salesforce introduces Enterprise AI Harness, AI Control Plane2h ago The Race for the Next Big Weight-Loss Drug Is On—and China Wants In3h ago How Social Media Platforms Are Identifying AI Content3h ago DeepSeek launches V4.1-Flash and retires V4-Pro, its flagship model3h ago OpenAI Wants to Know if an AI Industry Slowdown Would Even Be Legal3h ago Oracle Cloud Sales More Than Double, Topping Estimates on AI4h ago

Healthcare Machine Learning4 min reading time

Brainomix E-Lung Analysis Detects Treatment Effects in Phase 2a IPF Trial

Unite.AIPublished 3 days ago

Brainomix and Endeavor BioMedicines reported that Brainomix's AI-powered e-Lung tool detected significant treatment effects of taladegib in a Phase 2a idiopathic pulmonary fibrosis trial by analyzing CT scans. The AI analysis revealed improvements in lung volume, fibrosis extent, and disease burden, supporting its use for sensitive, objective endpoints in clinical trials.

#brainomix #clinical-trials #e-lung #endeavor-biomedicines #european-respiratory-society-congress #medical-imaging #pulmonary-fibrosis #taladegib

More in Healthcare

Google DeepMind Releases AlphaGenome Atlas Mapping 9 Billion Human DNA

Forbes7h ago

Healthcare3 min read

Mark Wahlberg is coming to TechCrunch Disrupt 2026, and he wants to talk about your work, not his

TechCrunch5h ago

UK Is Urged to Overhaul Regulation of AI-Medical Devices

Covered by 2 sources1d ago